News | December 07, 2008

TandemHeart Played a Critical Role in Saving Teen’s Life

December 8, 2008 - There has been much discussion in recent weeks of the 14-year-old patient from Holtz Children’s Hospital in Miami living without a heart for more than 100 days, but what has not been reported are the facts behind the struggle as to how initially and immediately treat the young patient in post-transplant failure.

This patient was fairing so poorly that she could not be weaned from cardio pulmonary bypass. She faced great odds of expiring and was not in any condition to immediately endure a complicated surgical BiVAD insertion or another transplant, even if another organ was immediately available, said officials at CardiacAssist Inc., the makers of the TandemHeart. BIVAD.

Her surgeons chose to use the TandemHeart device as a bridge to the surgical BIVAD when it was not possible to wean from bypass immediately post-transplant. The TandemHeart provided the surgeons with a means to provide bi-ventricular support without the complex and invasive cannulation techniques required of surgical VAD placement. This enabled physicians to get the support necessary with minimal metabolic stress to either the patient or her heart. With the support of the TandemHeart, the physicians had the time necessary to make important decisions regarding the subsequent treatment for this particular patient after a few days.

“The TandemHeart played a critical role in early treatment of this patient’s transplant failure,” said Marco Ricci, M.D., assistant professor of surgery at Holtz Children’s Hospital. “While it is true that the next 100 days were accomplished thanks to the surgical BIVAD, we were really in a tough spot with few viable choices when we were unable to wean her from bypass. The TandemHeart was an important step in this case.”
The TandemHeart can be placed rapidly in the cath lab or operating room, providing effective, reliable, temporary circulatory support. To date, the TandemHeart has been used nearly 1,500 times in 28 countries at 130 different facilities by 300 different physicians, the company said.

For more information:

Related Content

Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Abbott Recalls the HeartMate 3 Left Ventricular Assist System, LVAD
News | Ventricular Assist Devices (VAD) | May 23, 2018
Abbott has initiated a Class I recall of the HeartMate 3 Left Ventricular Assist System due to a malfunction in the...
FDA Approves Abiomed Impella CP With SmartAssist and Optical Sensor
Technology | Ventricular Assist Devices (VAD) | April 02, 2018
Abiomed Inc. announced that it received U.S. Food and Drug Administration (FDA) Pre-Market Approval (PMA) for its...
Reduced Device Clotting, Decreased Strokes Seen With HeartMate 3 at Two Years
News | Ventricular Assist Devices (VAD) | March 13, 2018
At two years of follow-up, severely ill patients with advanced heart failure who received a novel heart pump fully...
Medtronic HeartWare HVAD System Approved for Destination Therapy
Technology | Ventricular Assist Devices (VAD) | October 04, 2017
October 4, 2017 — Medtronic received U.S.
Overlay Init